Structure, function and inhibition of poly(ADP-ribose)polymerase, member 14 (PARP14)

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)
49 Downloads (Pure)

Abstract

Poly(ADP-ribose)polymerase, member 14 (PARP14, alternatively named ARTD8, BAL2, and COAST6) is an intracellular mono(ADP-ribosyl) transferase. PARP14 transfers a negatively charged ADP-ribose unit from a donor NAD+ molecule onto a target protein, post-translationally. PARP14’s domain architecture consists of three macrodomains (Macro1, Macro2 and Macro3), a WWE domain and an ARTD (or catalytic domain). The Macro2 and Macro3 domains bind ADP-ribose (ADPr) with high affinity, whereas the WWE domain stabilizes the protein structure by binding to ADPr derivatives. The catalytic domain is involved in binding the NAD+ and catalyzing the mono-ADP-ribosylation reaction. PARP14 has been identified as a possible anti-cancer and anti-inflammatory target. Acting as a transcriptional co-activator for STAT6, PARP14 acts to promote the over activation of the Th2 immune response, thus promoting the metabolic change to an anaerobic state (Warburg effect) and activation of cell survival pathways through JNK2 and the PGI/AMF complex. These changes are consistent with the metabolic sophistication observed in cancer, and the immune imbalance in inflammatory diseases. Current literature on selective and unselective PARP14 inhibitors are reviewed and discussed. Although there is no evidence that selective PARP inhibitors would be advantageous we have proposed some strategies for future design of selective PARP14 inhibitors.

Original languageEnglish
Pages (from-to)1659-1669
Number of pages11
JournalMini-Reviews in Medicinal Chemistry
Volume18
Issue number19
Early online date15 Aug 2018
DOIs
Publication statusPublished - 2018

Fingerprint

Poly(ADP-ribose) Polymerases
Adenosine Diphosphate Ribose
NAD
Catalytic Domain
ADP Ribose Transferases
Protein Binding
Adenosine Diphosphate
Neoplasms
Cell Survival
Anti-Inflammatory Agents

Cite this

@article{92a1aad510904bfda7968d26e88ed467,
title = "Structure, function and inhibition of poly(ADP-ribose)polymerase, member 14 (PARP14)",
abstract = "Poly(ADP-ribose)polymerase, member 14 (PARP14, alternatively named ARTD8, BAL2, and COAST6) is an intracellular mono(ADP-ribosyl) transferase. PARP14 transfers a negatively charged ADP-ribose unit from a donor NAD+ molecule onto a target protein, post-translationally. PARP14’s domain architecture consists of three macrodomains (Macro1, Macro2 and Macro3), a WWE domain and an ARTD (or catalytic domain). The Macro2 and Macro3 domains bind ADP-ribose (ADPr) with high affinity, whereas the WWE domain stabilizes the protein structure by binding to ADPr derivatives. The catalytic domain is involved in binding the NAD+ and catalyzing the mono-ADP-ribosylation reaction. PARP14 has been identified as a possible anti-cancer and anti-inflammatory target. Acting as a transcriptional co-activator for STAT6, PARP14 acts to promote the over activation of the Th2 immune response, thus promoting the metabolic change to an anaerobic state (Warburg effect) and activation of cell survival pathways through JNK2 and the PGI/AMF complex. These changes are consistent with the metabolic sophistication observed in cancer, and the immune imbalance in inflammatory diseases. Current literature on selective and unselective PARP14 inhibitors are reviewed and discussed. Although there is no evidence that selective PARP inhibitors would be advantageous we have proposed some strategies for future design of selective PARP14 inhibitors.",
author = "Schweiker, {Stephanie S} and Amanda Tauber and Madeleine Sherry and Levonis, {Stephan M}",
year = "2018",
doi = "10.2174/1389557518666180816111749",
language = "English",
volume = "18",
pages = "1659--1669",
journal = "Mini-Reviews in Medicinal Chemistry",
issn = "1389-5575",
publisher = "Bentham Science Publishers",
number = "19",

}

Structure, function and inhibition of poly(ADP-ribose)polymerase, member 14 (PARP14). / Schweiker, Stephanie S; Tauber, Amanda; Sherry, Madeleine; Levonis, Stephan M.

In: Mini-Reviews in Medicinal Chemistry, Vol. 18, No. 19, 2018, p. 1659-1669.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Structure, function and inhibition of poly(ADP-ribose)polymerase, member 14 (PARP14)

AU - Schweiker, Stephanie S

AU - Tauber, Amanda

AU - Sherry, Madeleine

AU - Levonis, Stephan M

PY - 2018

Y1 - 2018

N2 - Poly(ADP-ribose)polymerase, member 14 (PARP14, alternatively named ARTD8, BAL2, and COAST6) is an intracellular mono(ADP-ribosyl) transferase. PARP14 transfers a negatively charged ADP-ribose unit from a donor NAD+ molecule onto a target protein, post-translationally. PARP14’s domain architecture consists of three macrodomains (Macro1, Macro2 and Macro3), a WWE domain and an ARTD (or catalytic domain). The Macro2 and Macro3 domains bind ADP-ribose (ADPr) with high affinity, whereas the WWE domain stabilizes the protein structure by binding to ADPr derivatives. The catalytic domain is involved in binding the NAD+ and catalyzing the mono-ADP-ribosylation reaction. PARP14 has been identified as a possible anti-cancer and anti-inflammatory target. Acting as a transcriptional co-activator for STAT6, PARP14 acts to promote the over activation of the Th2 immune response, thus promoting the metabolic change to an anaerobic state (Warburg effect) and activation of cell survival pathways through JNK2 and the PGI/AMF complex. These changes are consistent with the metabolic sophistication observed in cancer, and the immune imbalance in inflammatory diseases. Current literature on selective and unselective PARP14 inhibitors are reviewed and discussed. Although there is no evidence that selective PARP inhibitors would be advantageous we have proposed some strategies for future design of selective PARP14 inhibitors.

AB - Poly(ADP-ribose)polymerase, member 14 (PARP14, alternatively named ARTD8, BAL2, and COAST6) is an intracellular mono(ADP-ribosyl) transferase. PARP14 transfers a negatively charged ADP-ribose unit from a donor NAD+ molecule onto a target protein, post-translationally. PARP14’s domain architecture consists of three macrodomains (Macro1, Macro2 and Macro3), a WWE domain and an ARTD (or catalytic domain). The Macro2 and Macro3 domains bind ADP-ribose (ADPr) with high affinity, whereas the WWE domain stabilizes the protein structure by binding to ADPr derivatives. The catalytic domain is involved in binding the NAD+ and catalyzing the mono-ADP-ribosylation reaction. PARP14 has been identified as a possible anti-cancer and anti-inflammatory target. Acting as a transcriptional co-activator for STAT6, PARP14 acts to promote the over activation of the Th2 immune response, thus promoting the metabolic change to an anaerobic state (Warburg effect) and activation of cell survival pathways through JNK2 and the PGI/AMF complex. These changes are consistent with the metabolic sophistication observed in cancer, and the immune imbalance in inflammatory diseases. Current literature on selective and unselective PARP14 inhibitors are reviewed and discussed. Although there is no evidence that selective PARP inhibitors would be advantageous we have proposed some strategies for future design of selective PARP14 inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85055200172&partnerID=8YFLogxK

U2 - 10.2174/1389557518666180816111749

DO - 10.2174/1389557518666180816111749

M3 - Article

VL - 18

SP - 1659

EP - 1669

JO - Mini-Reviews in Medicinal Chemistry

JF - Mini-Reviews in Medicinal Chemistry

SN - 1389-5575

IS - 19

ER -